VXRT:OTCMKTS
Vaxart Inc
$0.37
arrow_downward
-0.62%(-0.0023) 1D
Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
$0.37
High
$0.38
Low
$0.36
Mkt. cap
89.61M
Avg. vol.
293.63K
Volume
174.37K
P/E ratio
2.92
52-wk high
$0.84
52-wk low
$0.33
EPS
$0.13
Beta
1.15
Shares outstanding
243.70M
No. of employees
65
Open
$0.37
High
$0.38
Low
$0.36
Mkt. cap
89.61M
Avg. vol.
293.63K
Volume
174.37K
P/E ratio
2.92
52-wk high
$0.84
52-wk low
$0.33
EPS
$0.13
Beta
1.15
Shares outstanding
243.70M
No. of employees
65
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
Nasdaq
·
1 day ago
Chartstopper: November 13, 2026
Bloomberg.com
·
21 hours ago
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
FoundedMar 2004
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitevaxart.com